Table 3.
iStent Inject clinical studies: summary of results
| Study | Design | Treatment (n= number of eyes) | Follow-up (months) | Attrition rate (%) | Mean IOP change (% reduction) | Mean medications (% reduction) |
|---|---|---|---|---|---|---|
| Fea et al24 | RCT | Treatment (2 iStent Inject) (n=94) vs control (medication) (n=98) | 12 | Treatment 0.0 vs control 7.1 | Treatment 38.40 vs control 36.20* | NA |
| Arriola-Villalobos et al26 | Case series | Phaco +1 iStent Inject (n=3) Phaco +2 iStent Inject (n=17) |
12 | 0.0 | 35.68** | 76.9** |
| Voskanyan et al25 | Case series | 2 iStent Inject (n=99) | 12 | 7.1 | 39.70 | Data not provided |
Notes: The values listed under the columns “mean IOP change” and “mean medications” indicate the reduction from baseline. P-values where available from original publication:
*
P<0.05,
**
P<0.001.
Abbreviations: IOP, intraocular pressure; NA, not applicable; phaco, phacoemulsification; RCT, randomized controlled trial; vs, versus.